ARTICLE | Strategy

Platform Trifecta

J&J to keep Crucell independent, like previous platform plays Tibotec, Centocor

October 11, 2010 7:00 AM UTC

Johnson & Johnson has had good success with two platform-based acquisitions, one of antibody company Centocor Inc. in 1999 and another of antiviral company Tibotec-Virco N.V. in 2002. J&J aims to make it a trifecta with the purchase of vaccine-specialist Crucell N.V.

According to Paul Stoffels, J&J's global head of pharmaceutical R&D, the Crucell deal, like Tibotec and Centocor, brings a specialized platform in an area in which the pharma did not have expertise...